Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8770387 | The Journal of Urology | 2018 | 8 Pages |
Abstract
The lack of long-term high intensity focused ultrasound oncological data in an American population has brought new challenges to prostate cancer stakeholders, including clinicians, patients and the FDA. Patient preference information from future patient studies on high intensity focused ultrasound could provide additional information to patients, clinicians, and current and prospective device developers. In addition, it can be used by regulators in benefit-risk evaluations of this class of treatment devices.
Keywords
PSAFDAIIEFTTOquality adjusted life-yearQALYHIFUQOLUTIPPIQuality of lifeProstate specific antigenUnited States Food and Drug AdministrationBladder outlet obstructionBOOUrinary incontinenceTime trade-offEquipment and suppliesPatient preferenceClinical decision makingRadical prostatectomyFood and Drug Administrationhigh intensity focused ultrasoundInternational Index of Erectile Functionurinary tract infectionstandard gambleProstatic neoplasmsActive surveillance
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Olufemi Babalola, Ting-Hsuan (Joyce) Lee, Charles J. Viviano,